Entities / Company
Sun Pharmaceutical.
Indian multinational pharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 40
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
One to three months ago
-
Sun Pharmaceutical and Larsen & Toubro are featured in the top three holdings of two specific dividend yield funds, as of July 9, 2026.Some support1 report
-
Infosys declines ahead of IT earnings season, while JPMorgan's sector upgrade affects Sun Pharma amidst West Asia tension.Some support1 report
Gone quiet
No new reports in 90+ daysNo events began in the chosen period. Widen it, or reset.
Around Sun Pharmaceutical this week
News at the entities that move Sun Pharmaceutical most-
Donald Trump TransactionalThe Trump administration utilized the Department of Health & Human Services for an AI tool.Moves Sun Pharmaceutical
-
S&P Global Ratings TransactionalS&P Global Ratings raised its GDP growth forecast for Oman.Moves Sun Pharmaceutical
-
Fortress Biotech StructuralThe financial health and market performance of Fortress Biotech and Theravance Biopharma are currently under direct comparison.Moves Sun Pharmaceutical
-
Organon & Co. TransactionalOrganon & Co. and Spero Therapeutics Inc., two healthcare companies, are currently competing for investment opportunities.Moves Sun Pharmaceutical
-
Infosys Mentioned togetherOn September 28, 2026, the market experienced a crash: Infosys was the only Sensex stock to close higher, while Larsen & Toubro was the biggest loser.Moves Sun Pharmaceutical
Connections
The 5 strongest of 40, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Fortress Biotech Structural
Fortress Biotech's subsidiary, Checkpoint Therapeutics, was acquired by Sun Pharmaceutical, establishing a structural relationship.
-
Organon & Co. Transactional
Sun Pharmaceutical has proposed an $11.75 billion acquisition bid for Organon & Co.
-
Donald Trump Transactional
Donald Trump secured and announced drug-pricing agreements with Sun Pharmaceutical.
-
S&P Global Ratings Transactional
S&P Global Ratings formally assessed Sun Pharmaceutical with a BBB+ long-term issuer credit rating.
-
Infosys Mentioned together
The companies were mentioned together in a market analysis comparing the performance trends of the IT and pharmaceutical sectors.